ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0541

Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study

Irini Flouri1, Nestor Avgoustidis2, Anastasios Eskitzis2, Argyro Repa2, Katerina Pateromichelaki2, Sofia Pitsigavdaki3, Myrto Nikoloudaki2, Maria Terizaki2, George Bertsias4 and Prodromos Sidiropoulos4, 1University of Crete Medical School, Heraklion, Greece, 2Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, 3Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, 4Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Disease Activity, Psoriatic arthritis, registry, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral Spondyloarthritis (perSpA) in real-world clinical practice is scarce. Our aims were to assess the level of disease activity of SpA patients in real-world practice, the extent of T2T strategy implementation and the reasons of possible non-implementation.

Methods: Cross-sectional study of all consecutive patients with SpA who visited the outpatient department or the one-day infusions’ clinic of our hospital during a 7-month period (6/2021-12/2021). Detailed patient, disease and treatment characteristics were collected, as well as disease activity of axial (using ASDAS-CRP), peripheral (DAPSA) and extraarticular manifestations. Additionally, physicians filled-in questionnaires regarding treatment intensification or not (and reasons) in patients not in target at the specific visit. Multivariable logistic regression analysis was employed to identify predictors of therapy intensifications in patients not in target.

Results: We analyzed243 patients (54% males; AxSpA:187, perSpA:56)with median (IQR) age of 52 (42-61) and disease duration 4.1 (2.1-12.3) years. The main therapy in the majority of the patients (83%) was a biologic (b-)DMARD.In patients with AxSpA, median (IQR) ASDAS-CRP was 2.4 (1.7-3.1), while in perSpA patients, median (IQR) DAPSA score was 26 (12.4-36.2). Low disease activity or inactive disease (LDA/ID), taking into account axial and/or peripheral as well as extraarticular manifestations was found in 26% and 25% of the patients in AxSpA and perSpA respectively.

Of the patients not having at least LDA (N=181), 82 (45%) had their treatment intensified. Physician-documented reasons of non-intensification are shown in Figure. In multivariable analysis, the type of patients’ main therapy [OR(95%CI) for non-bDMARD vs bDMARD:12.2 (4.8-41.4)], physician’s VAS score [OR:1.22 (1.10-1.27)]and patients’ VAS global score [OR:1.08 (1.02-1.12)]were predicting therapy intensifications in patients not in target.

Conclusion: In this real-world study, the majority of SpA patients had high disease activity levels. T2T strategy was implemented in approximately half of those patients, especially those on non-biologic main therapy and high physician VAS score.


Disclosures: I. Flouri: None; N. Avgoustidis: None; A. Eskitzis: None; A. Repa: None; K. Pateromichelaki: None; S. Pitsigavdaki: None; M. Nikoloudaki: None; M. Terizaki: None; G. Bertsias: None; P. Sidiropoulos: None.

To cite this abstract in AMA style:

Flouri I, Avgoustidis N, Eskitzis A, Repa A, Pateromichelaki K, Pitsigavdaki S, Nikoloudaki M, Terizaki M, Bertsias G, Sidiropoulos P. Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/treat-to-target-strategy-implementation-in-spondyloarthritis-patients-of-real-world-clinical-practice-a-cross-sectional-single-center-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treat-to-target-strategy-implementation-in-spondyloarthritis-patients-of-real-world-clinical-practice-a-cross-sectional-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology